New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:38 EDTMDT, BCRMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Wells fargo believes that data from a trial of Medtronic's drug-coated balloon will lead to approval of the device in 1H15 and establish the company as the market leader in the space. After analyzing data, the firm thinks data on a competing device from C.R. Bard (BCR) could be significantly less positive than the data on Medtronic's product. As a result, the firm anticipates that Medtronic will have a marketing advantage over C.R. Bard. Wells keeps an Outperform rating on Medtronic.
News For MDT;BCR From The Last 14 Days
Check below for free stories on MDT;BCR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
12:46 EDTMDTMedtronic receives FDA approval for PRESTIGE cervical disc system
Subscribe for More Information
11:07 EDTMDTLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
06:52 EDTMDTFormer official says Obama could limit inversion deals, NY Times reports
President Obama could limit tax inversion deals on his own authority, said Stephen Shay, former deputy assistant Treasury secretary for international tax affairs in the Obama administration, according to The New York Times. A 1969 law gives the president the ability to restrict inversion deals, said Shay, who also worked in the Reagan administration, the newspaper stated. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN). Reference Link
July 25, 2014
06:30 EDTMDTObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
July 24, 2014
17:36 EDTBCRC.R. Bard raises FY14 EPS view to $8.25-$8.35 from $8.20-$8.30
Subscribe for More Information
17:34 EDTBCRC.R. Bard sees Q3 EPS $2.07-$2.11, consensus $2.09
Subscribe for More Information
16:25 EDTBCRC.R. Bard reports Q2 adjusted EPS $2.06, consensus $2.01
Subscribe for More Information
08:19 EDTMDTLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
July 21, 2014
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
July 18, 2014
12:51 EDTMDTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 16, 2014
10:36 EDTMDTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
07:59 EDTMDTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:18 EDTMDTScoliosis Research Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use